Outcome of elective cemiplimab discontinuation in locally advanced or metastatic cutaneous squamous cell carcinoma patients achieving a complete remission

Our retrospective data review demonstrated that early elective cemiplimab discontinuation was both feasible, and safe. There was a low risk of relapse if patients achieve a radiologically or pathologically documented complete remission. We believe that decreases in the duration of cemiplimab treatment has the potential to reduce the risk of delayed checkpoint inhibitor toxicity, as well as decreasing treatment costs. Confirmation of our encouraging findings in a prospective clinical trial is recommended.